TMEM19

Across TCGA pan-cancer cohorts, TMEM19 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TMEM19 data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TMEM19 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TMEM19 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

HNSC, CCRCC, and LSCC are the cancer types where TMEM19 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	All	0.938	0.746	.010	10	view →
CCRCC	DFS	Median	All	0.967	0.862	.007	9	view →
LSCC	DFS	Quartile	All	1.000	0.879	.016	6	view →
PDAC	OS	Quartile	III,IV	0.544	0.971	.010	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TMEM19–HNSC (DFS)

Open the HNSC breakdown →